FDA Decision on Ifinatamab Deruxtecan for Small Cell Lung Cancer Expected by Oct. 10
FDA Decision on Ifinatamab Deruxtecan for Small Cell Lung Cancer Expected by Oct. 10 Cure Today
🎗️
Онкология
Рак лёгких
277 материалов по теме, собраны автоматически из проверенных источников
Онкология
Two Decades of Data Reveal How Small Molecule Drugs Reshaped Lung Cancer Treatment
Two Decades of Data Reveal How Small Molecule Drugs Reshaped Lung Cancer Treatment Bioengineer.org
🎗️
Онкология
Tarlatamab Shows Benefits in Small Cell Lung Cancer Brain Metastases
Tarlatamab Shows Benefits in Small Cell Lung Cancer Brain Metastases Oncology News Central
Онкология
A cancer drug will be tested in lung cancer; its prostate-cancer trial is enrolling.
A cancer drug will be tested in lung cancer; its prostate-cancer trial is enrolling. Stock Titan
Онкология
У женщины, не имевшей никаких респираторных симптомов, неожиданно диагностировали рак легких.
У женщины, не имевшей никаких респираторных симптомов, неожиданно диагностировали рак легких. Vietnam.vn
Онкология
EGFR Lung Cancer Patients Await a November 14 FDA Decision on Ivonescimab Plus Chemotherapy After Tagrisso Stops Working
EGFR Lung Cancer Patients Await a November 14 FDA Decision on Ivonescimab Plus Chemotherapy After Tagrisso Stops Working medicaldaily.com
Онкология
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape OncLive
Онкология
Real-World Data Reveal a Sobering Gap in Lung Cancer Care After Osimertinib Fails
Real-World Data Reveal a Sobering Gap in Lung Cancer Care After Osimertinib Fails Bioengineer.org
Онкология
Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs
About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.
Онкология
Blood RNA markers may flag lung cancer risk 10 years before diagnosis
Genetic markers in the blood that can signal lung cancer risk up to 10 years before a person is diagnosed have been discovered by University of Hawaiʻi researchers. The set of 31 tiny markers, called small noncoding RNAs, could eventually help identify people at higher risk while cancer remains clinically undetected.
Онкология
У 40-летней женщины, не имевшей респираторных симптомов, был диагностирован рак легких.
У 40-летней женщины, не имевшей респираторных симптомов, был диагностирован рак легких. Vietnam.vn
Онкология
Всего через два месяца после операции по удалению рака щитовидной железы у 40-летней женщины был диагностирован рак легких.
Всего через два месяца после операции по удалению рака щитовидной железы у 40-летней женщины был диагностирован рак легких. Vietnam.vn
Онкология
Merck and Daiichi Withdraw Small Cell Lung Cancer Drug Bid After FDA Signals Phase 2 Data Fell Short
Merck and Daiichi Withdraw Small Cell Lung Cancer Drug Bid After FDA Signals Phase 2 Data Fell Short Medical Daily
Онкология
Cancer Research UK Lung Cancer Centre of Excellence – Conference 2026
Cancer Research UK Lung Cancer Centre of Excellence – Conference 2026 Oncodaily
Онкология
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) BioSpace